Details of the Drug Formulations

General Information of Drug (ID: DMK7IWL)

• Drug Name: Relugolix Drug Info
• Synonyms: 737789-87-6; TAK-385; TAK 385; UNII-P76B05O5V6; CHEMBL1800159; TAK-385/TAK385; P76B05O5V6; 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea; Relugolix [USAN:INN]; TAK385; Relugolix (JAN/INN); SCHEMBL778416; GTPL5586; DTXSID40224167; MolPort-044-567-649; AOMXMOCNKJTRQP-UHFFFAOYSA-N; EX-A1083; BCP21587; ZINC43206033; BDBM50347982; AKOS027440398; SB16721; DB11853; CS-5917

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Approved	[1]
Endometriosis	GA10	Phase 3	[2]

• Cross-matching ID:
  PubChem CID: 10348973
  CAS Number: 737789-87-6
  TTD ID: D0F2WP
  VARIDT ID: DR00186
  ACDINA ID: D01379

Full List of Drug Formulations Containing This Drug

Relugolix 120 mg tablet

Company	Formulation ID	FDA Description
Myovant Sciences	F23267	Mannitol; Sodium Starch Glycolate; Hydroxypropyl Cellulose; Magnesium Stearate; Hypromellose; Titanium Dioxide; Ferric Oxide Red; Carnauba Wax

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)